The GENE WRITING platform can change any base pair to any other, make small insertions or deletions, and write entire genes into the genome with delivery of only RNA.
#Tessera therapeutics stock code#
Tessera’s GENE WRITING technology is designed to cure disease by writing in the code of life. "This latest funding round is a testament to the immense potential of this bioplatform to provide new treatments and cures to previously untreatable genetic diseases." "While there have been many advancements in the area of genetic medicine over the past decade, Tessera’s GENE WRITING platform is charting an entirely new course-one that aims to revolutionize genetic medicine as we know it," said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. "Today’s announcement will help us realize the promise of GENE WRITING technology and our mission of curing disease by writing in the code of life." It is our belief that genetic medicine will be the most important next epoch in medicine-offering the ability to cure genetic diseases and to someday even prevent disease from occurring," said Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director of Tessera Therapeutics. "We are thankful for the support from our new partners and existing investors alike in this latest funding round. Rowe Price Associates, Inc., and others including all of Tessera’s existing institutional shareholders. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) Alaska Permanent Fund Corporation Altitude Life Science Ventures ARTIS Ventures Cormorant Asset Management Tessera’s founder, Flagship Pioneering Hanwha Impact Partners Longevity Vision Fund March Capital SALT Fund SoftBank Vision Fund 2 funds and accounts advised by T.
#Tessera therapeutics stock series#
SOMERVILLE, Mass., April 19, 2022-( BUSINESS WIRE)-Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing. Latest Financing Round Will Support Tessera’s Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development
0 kommentar(er)
